Pharma & Biotech Global Week in Review 30 May 2012 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

World Health Assembly: Agreement reached on neglected disease R&D process, but no convention (IP Watch) (IP Watch) (IP Watch) (KEI) (KEI) (KEI) (IP Watch)

Argentina goes the 3(d) way: Creases of worry for the pharmaceutical patent applicants? (Spicy IP)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

Obligations to fund R&D, under Consultative Expert Working Group (CEWG) recommendation (KEI)

World Health Assembly: Agreement reached on neglected disease R&D process, but no convention (IP Watch) (IP Watch) (IP Watch) (KEI) (KEI) (KEI) (IP Watch)

Why did Obama oppose the medical R&D treaty at the 65th World Health Assembly in May 2012? (KEI)

World Health Assembly: Members agree on NCD resolution (IP Watch) (IP Watch)

World Health Assembly: Members gavel new mechanism to fight poor-quality medicines (IP Watch)

WIPO Standing Committee on the Law of Patents 18th Session: Open letter to those who collectively produced the May 23, 2012 statement to the WIPO SCP on the topics of patents and health (KEI)

WIPO Standing Committee on the Law of Patents 18th Session: Patent protection and drug affordability – US statement on US proposal on patents and health (KEI) (IAM)

WIPO Standing Committee on the Law of Patents 18th Session: Intervention of Chile regarding patents and health – existing flexibilities in the international patent system (KEI)

What’s a counterfeit? And how many counterfeit drugs are there? (KEI)

Argentina goes the 3(d) way: Creases of worry for the pharmaceutical patent applicants? (Spicy IP)

US: Senate passes S. 3187 FDA Safety and Innovation Act (FDA Law Blog) (Patent Docs)

US: Making the House FDA Reform Act of 2012 PAYGO compliant – Are expedited 505(q) citizen petition responses the answer? (FDA Law Blog)

US: FDA’s PLAIR program collides with Hatch-Waxman: Sanofi v Apotex (Clopidogrel) (FDA Law Blog)

US: Group looks at effects of America Invents Act on plant breeders (IP Watch)

US: Myriad misunderstanding of Parke-Davis v Mulford (Patently-O)

US: Puzzled by Prometheus – thoughts from roundtable hosted by BIO and George Washington University Law School (Pharma Patents)

 

Products

Acetadote (N-acetylcysteine) – US: Cumberland files patent infringement suits against Paddock Laboratories and Mylan in response to Para IV challenge (Patent Docs)

Aloxi (Palonosetron) – US: Helsinn Healthcare files patent infringement suit against Dr Reddy’s in response to Para IV certification as part of NDA filing (Patent Docs)

Aplenzin (Bupropion) – US: Valeant files patent infringement suit against Sandoz in response to Para IV certification as part of ANDA filing (Patent Docs)

Crestor (Rosuvastatin) – Australia: Crestor catch-up.  Injunctions granted against three rival generic product manufactures (Patentology)

Exforge HCT (Amlodipine, Valsartan and Hydrochlorothiazide) – US: Novartis files patent infringement complaints against Lupin and Torrent Pharmaceuticals following Para IV certification filing as part of ANDA (Patent Docs)

Frontline Combo (Fipronil and (S)-methoprene) – France: Only genuine competitor has standing to bring patent revocation action: Omnipharm v Merial (EPLAW)

Gralise (Gabapentin) – US: Depomed files patent infringement suit against Zydus and Cadila in response to Para IV challenge (Patent Docs)

Latisse (Bimatoprost) – US: Allergan files patent infringement suit against Hi-Tech Pharmacal in response to Para challenge (Patent Docs)

Lialda (Mesalamine) – US: Shire files patent infringement suit against Watson in response to Para IV certification (Patent Docs)

Loestrin Fe (Norethindrone, ethinyl estradiol, ferrous fumarate) – Warner Chilcott files patent infringement suit against Watson in response to Para IV challenge (Patent Docs)

Prezista (Darunavir) – US: Janssen files patent infringement suit against Lupin in response to Para IV certification (Patent Docs)

Roundup Ready soybean seed – US: Monsanto files patent infringement suit against Myron Alexander and others based on use of seed produced from earlier planted Roundup Ready seed (Patent Docs)

One Comment on “Pharma & Biotech Global Week in Review 30 May 2012 from IP Think Tank

  1.  Canada: Supreme Court issues decision in Merck Frosst v Canada (Health) concerning Access to Information request regarding new drug submission by competitor.
    Escitalopram – Netherlands: District Court of The Hague finds escitalopram patent partially valid: Lundbeck v Tiefenbacher

    Like

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 20,525 other followers

%d bloggers like this: